Eiger Bio Pharmaceuticals, Inc. EIGR
We take great care to ensure that the data presented and summarized in this overview for Eiger BioPharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EIGR
View all-
Telemetry Investments, L.L.C. New York, NY345KShares$1.14 Million0.64% of portfolio
-
Act Capital Management, LLC Wayne, PA235KShares$775,5002.44% of portfolio
-
Drw Securities, L.L.C. Chicago, IL120KShares$397,2040.02% of portfolio
-
Dfpg Investments, LLC32.4KShares$107,0190.0% of portfolio
-
Zeke Capital Advisors, LLC Berwyn, PA13KShares$42,9000.0% of portfolio
-
American Portfolios Advisors Holbrook, NY2.25KShares$7,4250.0% of portfolio
Latest Institutional Activity in EIGR
Top Purchases
Top Sells
About EIGR
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
Insider Transactions at EIGR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 02
2023
|
Richard A Kayne |
BUY
Open market or private purchase
|
Indirect |
23,398
+0.43%
|
$0
$0.3 P/Share
|
|
Nov 01
2023
|
Richard A Kayne |
BUY
Open market or private purchase
|
Indirect |
100,000
+1.83%
|
$0
$0.28 P/Share
|
|
Oct 31
2023
|
Richard A Kayne |
BUY
Open market or private purchase
|
Indirect |
154,841
+0.97%
|
$0
$0.25 P/Share
|
|
Oct 31
2023
|
Leen Kawas |
BUY
Open market or private purchase
|
Indirect |
24,332
+0.28%
|
$0
$0.26 P/Share
|
|
Mar 17
2023
|
Eldon C. Mayer Iii Ex VP & Chief Commerc. Officer |
SELL
Open market or private sale
|
Direct |
4,395
-3.7%
|
$4,395
$1.07 P/Share
|
|
Jan 23
2023
|
Thomas John Dietz |
BUY
Open market or private purchase
|
Indirect |
50,000
+50.0%
|
$50,000
$1.43 P/Share
|
|
Dec 29
2022
|
Christine Murray |
SELL
Open market or private sale
|
Direct |
5,000
-31.25%
|
$5,000
$1.22 P/Share
|
|
Dec 22
2022
|
Jeffrey S Glenn |
BUY
Open market or private purchase
|
Direct |
100,000
+35.42%
|
$100,000
$1.28 P/Share
|
|
Dec 22
2022
|
Thomas John Dietz |
SELL
Open market or private sale
|
Direct |
22,500
-51.72%
|
$22,500
$1.17 P/Share
|
|
Aug 16
2022
|
David Apelian CEO |
SELL
Open market or private sale
|
Direct |
5,000
-31.25%
|
$45,000
$9.81 P/Share
|
|
Mar 14
2022
|
Eldon C. Mayer Iii Ex VP & Chief Commerc. Officer |
SELL
Open market or private sale
|
Direct |
1,657
-2.67%
|
$8,285
$5.6 P/Share
|
|
Mar 14
2022
|
Sriram Ryali Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,266
-5.17%
|
$11,330
$5.6 P/Share
|
|
Mar 11
2022
|
David Apelian CEO |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+27.27%
|
-
|
|
Mar 11
2022
|
Erik Atkisson GC & Chief Compliance Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+50.0%
|
-
|
|
Mar 11
2022
|
David A Cory President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
47,000
+21.74%
|
-
|
|
Mar 11
2022
|
Thomas John Dietz |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+12.12%
|
-
|
|
Mar 11
2022
|
Evan Loh |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+30.0%
|
-
|
|
Mar 11
2022
|
Jeffrey S Glenn |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+6.79%
|
-
|
|
Mar 11
2022
|
Eldon C. Mayer Iii Ex VP & Chief Commerc. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+20.48%
|
-
|
|
Mar 11
2022
|
Christine Murray |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+27.27%
|
-
|
Last 12 Months Summary
| Open market or private purchase | 303K shares |
|---|